Tag: pubmed

Psychol Assess. 2026 Jul 20. doi: 10.1037/pas0001476. Online ahead of print.

ABSTRACT

Multi-informant assessments are considered the gold standard in the assessment of youth psychopathology. Although best practice dictates that this approach should extend to the assessment of youth involved in the justice system, few studies have examined the effect of multiple informants in a forensic context. Using a sample of 580 youth-caregiver dyads, we conducted a series of polynomial regressions to test whether statistical interactions between scores on the Youth Self-Report and scores on the Child Behavior Checklist (completed by caregivers) predicted psychiatric diagnoses. Psychiatric diagnoses were coded from the youth’s final forensic assessment report and included anxiety disorder, depressive disorder, conduct disorder, oppositional defiant disorder, and attention-deficit hyperactivity disorder. A significant interaction was found when modeling the effect of youth-caregiver reports of rule-breaking behavior on receiving a conduct disorder diagnosis, and when modeling the effect of youth-caregiver reports of aggressive behavior on receiving an attention-deficit hyperactivity diagnosis. No significant interactions were found when modeling the effect of youth-caregiver reports of internalizing symptomology on receiving an anxiety or depressive disorder diagnosis. Results suggest that youth and caregiver reports are integrated differently depending on whether the clinician is making an internalizing or externalizing spectrum diagnosis. Study implications for forensic assessments with multiple informants are discussed. (PsycInfo Database Record (c) 2026 APA, all rights reserved).

PMID:42475031 | DOI:10.1037/pas0001476

J Relig Health. 2026 Jul 20. doi: 10.1007/s10943-026-02734-y. Online ahead of print.

ABSTRACT

Spiritual abuse is a form of harm in religious communities that disrupts positive social connections and causes negative health impacts. Without objective assessment methods, religious groups that are spiritually abusive can be difficult to identify. This study introduces spiritual safety-the ability to practice one’s spirituality without coercion, manipulation, or emotional abuse-as a measure for the risk of spiritual abuse in a faith-based organization. Sixty items were developed based on themes from the literature on spiritual abuse and psychological safety. The items were refined through content validity index and psychometrically validated across two separate studies with primarily North American Christian participants. In Study 1 (n = 331), exploratory factor analysis identified three underlying factors which were named psychological safety, leadership, and culture. Study 2 (n = 491) confirmed the three-factor structure using confirmatory factor analysis and validated a final 20-item version of the scale. The Spiritual Safety Scale (S-SAFE) demonstrated excellent reliability (α = 0.97), a strong correlation with individual psychological safety (r = 0.82), a strong negative correlation with PTSD symptomatology (r = – 0.56), and a moderate negative correlation with negative religious coping (r = – 0.43). Fit indices demonstrated good model fit (CFI = 0.95, TLI = 0.94, RMSEA = 0.07). ANOVA supported the statistical significance of scoring groups for healthy, unhealthy, and unsafe categories. The S-SAFE therefore offers a practical tool for assessing spiritual safety and risk of spiritual abuse in North American Christian communities.

PMID:42474978 | DOI:10.1007/s10943-026-02734-y

J Patient Rep Outcomes. 2026 Jul 20. doi: 10.1186/s41687-026-01149-3. Online ahead of print.

ABSTRACT

BACKGROUND: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, chronic disease that significantly affects quality of life (QoL). Despite improved survival, many patients experience persistent symptoms and complex care needs. Patient-reported data on QoL and perceived care quality remain limited, particularly in Italy. This study aimed to assess health-related QoL and patient-perceived care quality among Italian EGPA patients and to identify distinct patient profiles through cluster analysis to inform personalized, multidisciplinary care strategies.

METHODOLOGY: We conducted a cross-sectional, 77-item online survey among adult EGPA patients (self-reported diagnosis) between December 2024 and January 2025. The survey, developed with APACS APS (Associazione Pazienti con Sindrome di Churg-Strauss), was distributed via the SurveyMonkey platform. It included validated instruments: SF-36 for health-related QoL and PACIC (with PACIC-5As) for perceptions of chronic care. Additional demographic, clinical, and disease impact data were collected. Descriptive statistics and group comparisons were performed. SF-36 and PACIC domains were analyzed using principal component analysis (PCA), followed by k-means clustering to identify patient subgroups.

RESULTS: Seventy-two patients completed the survey (mean age 56; 65% female; median disease duration 7 years; 84.7% on biologics; 41.7% on glucocorticoids). SF-36 scores showed moderate QoL impairment (mean PCS 56.3 ± 24.6; MCS 59.3 ± 24.1), with lower QoL among females, divorced/separated individuals, and those with neurological involvement. Paresthesia had the greatest impact, affecting multiple QoL domains and daily functioning (p < 0.05). PACIC scores reflected moderate perceptions of care (2.8-3.5), with lowest scores in “Goal Setting” and “Care Coordination.” PACIC-5As scores were low (mean 2.3), indicating suboptimal collaborative care. Cluster analysis identified three profiles: (1) poor QoL with high healthcare engagement (n = 12); (2) best QoL and care ratings (n = 38); (3) intermediate health status but lowest PACIC scores (n = 22), reflecting perceived lack of support. Differences across clusters were statistically significant (p < 0.001).

CONCLUSIONS: Italian EGPA patients report impaired QoL and only moderate care quality, with notable heterogeneity in experiences. Personalized, multidisciplinary approaches are needed, especially for patients who feel under-supported despite moderate disease activity.

PMID:42474947 | DOI:10.1186/s41687-026-01149-3

J Occup Rehabil. 2026 Jul 20. doi: 10.1007/s10926-026-10416-5. Online ahead of print.

ABSTRACT

PURPOSE: Many people diagnosed with cancer are of working age and experience challenges returning to and retaining-paid work. Existing interventions to support return to work have shown mixed effectiveness, and their cost-effectiveness is often unknown. The STEPS work participation program, based on the Stages of Change, aims to support employed cancer survivors in work resumption and retention. This study evaluated its cost-effectiveness compared to usual care.

METHODS: An economic evaluation was conducted alongside a 12-month multi-center randomized controlled trial in the Netherlands. Employed cancer survivors were randomized to STEPS (n = 123) or usual care (n = 116). Quality-adjusted life years (QALYs) were estimated using the EQ-5D-5L questionnaire. Costs were assessed from a societal perspective. Analyses followed the intention-to-treat principle, were conducted using seemingly unrelated regression adjusted for baseline utility and costs, with uncertainty assessed using bootstrapping.

RESULTS: Participants in the STEPS group accrued marginally more QALYs than those receiving usual care (adjusted mean difference: 0.004; 95%CI: – 0.018 to 0.025), but this difference was neither statistically significant nor clinically relevant. Total societal costs were higher in the STEPS group than in usual care, with an adjusted mean difference of €2933 (95%CI: – €2735 to €8600). The probability of STEPS being cost-effective compared to usual care was 0.17 at a willingness-to-pay of €20,000/QALY, increasing only to 0.21 at €80,000/QALY. Sensitivity analyses confirmed these findings.

CONCLUSION: The STEPS program cannot be considered cost-effective compared to usual care and is therefore not recommended for implementation in its current form.

PMID:42474940 | DOI:10.1007/s10926-026-10416-5

J Robot Surg. 2026 Jul 20;20(1):714. doi: 10.1007/s11701-026-03704-y.

ABSTRACT

Most early reports on the Hugo™ Robotic- assisted surgery (RAS) system originated from institutions with concurrent access to established robotic platforms, potentially introducing device selection bias. We conducted a retrospective assessment of 103 patients with localized prostate cancer treated using Hugo™ RAS-assisted robot-assisted radical prostatectomy at a Japanese municipal hospital where no alternative robotic platform was available. The analysis focused on perioperative performance, safety outcomes, and consistency of procedural implementation. A standardized surgical setup, including a W-shaped port configuration and predefined floor-marking-based docking strategy, was applied. Surgery was carried out by six surgeons with different levels of robotic experience, including one surgeon without prior robotic operative experience. Operative, console, and docking durations showed median values of 152 min (IQR 129-218.5), 108 min (IQR 85-174.5), and 5 min (IQR 4-7), respectively. Estimated intraoperative blood loss was 100 mL (IQR 50-214). Neither intraoperative blood transfusion nor conversion to open surgery was necessary in any patient. Postoperative complications occurred in four patients (3.9%), including one major complication (Clavien-Dindo > II; 1.0%). Positive surgical margins were observed in 35 patients (34.0%) and 79.6% achieved urinary continence at 3 months. In this Hugo-exclusive, single-platform environment, RARP using the Hugo™ RAS system was performed without major safety concerns across surgeons with varying experience. Although four independent-arm carts needed to be rolled in, the median docking time was 5 min, possibly facilitated by a standardized floor-marking strategy adopted at our institution.

PMID:42474937 | DOI:10.1007/s11701-026-03704-y

J Gastrointest Cancer. 2026 Jul 20;57(1):159. doi: 10.1007/s12029-026-01535-6.

ABSTRACT

BACKGROUND: Metastatic colorectal cancer (mCRC) with microsatellite instability-high or mismatch repair deficiency (MSI-H/dMMR) demonstrates limited responsiveness to conventional cytotoxic chemotherapy but increased susceptibility to immune checkpoint inhibition. Although randomized phase III trials have shown superiority of immune checkpoint inhibitors (ICIs) in the first-line setting, a comprehensive synthesis of survival outcomes across key molecular and clinical subgroups remains warranted.

METHODS: We conducted a systematic review and meta-analysis of randomized, open-label, phase III trials comparing first-line ICI-based therapy with standard chemotherapy in MSI-H/dMMR mCRC. The primary endpoints were progression-free survival (PFS) and overall survival (OS). Prespecified subgroup analyses evaluated outcomes according to BRAF mutation status, KRAS/NRAS mutation status, and primary tumor location. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using random-effects models. Safety outcomes were analyzed using Mantel-Haenszel fixed-effect models. Statistical heterogeneity was assessed using the I² statistic.

RESULTS: Two phase III trials (KEYNOTE-177 and CheckMate-8HW), including more than 600 patients, were eligible. ICI-based therapy significantly improved PFS compared with chemotherapy (pooled HR 0.61; 95% CI, 0.51-0.73; I²=0%) and demonstrated a significant OS benefit (pooled HR 0.77; 95% CI, 0.63-0.94; I²=0%). Immunotherapy was associated with lower rates of overall and grade ≥ 3 adverse events, despite more frequent immune-related toxicities.

CONCLUSIONS: First-line ICI-based therapy provides significant and consistent survival benefits across BRAF-mutated and wild-type tumors, KRAS/NRAS-mutated and wild-type disease, and both right- and left-sided primary tumors, supporting its role as the standard of care for MSI-H/dMMR mCRC.

PMID:42474934 | DOI:10.1007/s12029-026-01535-6

Endocr Relat Cancer. 2026 Jul 20:ERC-26-0207. doi: 10.1530/ERC-26-0207. Online ahead of print.

ABSTRACT

Patients with pancreatic neuroendocrine tumours (PNETs) often have similar baseline clinical characteristics, including grade and molecular imaging phenotype, yet have highly variable responses to peptide receptor radionuclide therapy (PRRT). To identify genomic alterations and mutational patterns associated with PRRT treatment response as well as acquired somatic changes following PRRT exposure, whole genome or exome sequencing was applied to 40 PNET samples from 32 patients, including eight paired pre- or post-PRRT samples. The genomic profile of tumours reflected the known mutational landscape of PNET with MEN1 (34%), ATRX/DAXX (47%) alterations and a recurrent pattern of aneuploidy (38%) detected. A recurrent PSIP1::TBL1X fusion of unknown function was also identified in four tumours. The disease control rate following PRRT using RECIST1.1 and molecular imaging criteria was 88% (28/32). No mutational features were found to be statistically associated with progression-free survival. There was no significant increase in tumour mutational burden in the post-PRRT tumours, nor recurrent emergent mutational changes in cancer driver genes to explain progression to higher grade disease, when observed. However, a small indel signature (ID8) previously associated with DNA damage repair by non-homologous end joining (NHEJ), was higher in PRRT-exposed compared with PRRT-naïve samples (23.8% vs 4.8% respectively; p<0.001). Thus, comprehensive DNA analysis of pancreatic NETs did not identify biomarkers predictive of PRRT response nor evidence for high-level PRRT-induced genomic instability or hypermutation, yet mutation signature analysis supports NHEJ as being important for DNA repair and survival of neuroendocrine cells following exposure to beta-particle radiation.

PMID:42473856 | DOI:10.1530/ERC-26-0207

Langmuir. 2026 Jul 20. doi: 10.1021/acs.langmuir.6c01718. Online ahead of print.

ABSTRACT

Unraveling the subtle role of molecular interactions controlling the rheological and thermomechanical responses of graphene-reinforced asphalt binders using molecular dynamics (MD) simulations is a cornerstone problem in statistical thermodynamics because of its chemical heterogeneity, nonergodicity, and sluggish dynamics associated with viscoelastic relaxation. Herein, we emphasize devising generalized models of asphalt binders, resolving finite size effects and phase separation during thermodynamic equilibration of large-scale models, and quantitatively assessing diverse structural and dynamical properties including density, solubility parameter, diffusivity, viscosity, mechanical, and thermophysical properties of pristine asphalt and graphene-modified binders. This study provides a molecular framework for optimizing the thermodynamic compatibility between asphalt components and graphene nanofiller and enhancing thermomechanical properties by tailoring filler percentages. The uniaxial deformation simulations performed at different strain rates demonstrate that the yield stress and postyield softening can be improved just by adding 2 wt. % of graphene filler. The increased toughness in graphene-modified binders strongly correlates with the predicted higher noncovalent intermolecular forces, lower diffusivity of asphalt components, and increased zero-shear equilibrium viscosity compared to the pristine asphalt. The glass transition temperature of asphalt is enhanced by about 26 K for the 2 wt. % graphene-reinforced asphalt composite. Density functional theory (DFT), natural energy decomposition analysis (NEDA), noncovalent interaction (NCI) analysis, and steered molecular dynamics (SMD) simulations were employed to probe the molecular mechanisms governing graphene-asphalt interactions. The multiscale simulations reveal that the strong interfacial interactions between graphene and polar asphalt components, dominated by π-π stacking and dispersion forces, are responsible for the mechanical reinforcement of the asphalt matrix. The resemblance of predicted data with experimental results in many cases further substantiates the applicability of a theoretical framework for the rational design of graphene-modified asphalt binders with desired physicochemical properties.

PMID:42473850 | DOI:10.1021/acs.langmuir.6c01718

Int J Health Plann Manage. 2026 Jul 20. doi: 10.1002/hpm.70101. Online ahead of print.

ABSTRACT

Rising out-of-pocket (OOP) health expenditures in the Eastern Caribbean Currency Union (ECCU) underscore persistent gaps in health insurance coverage. This paper develops a Health Insurance Policy Simulation Model (HIPSM) to assess the potential impact of employer health insurance mandates and health insurance tax credits (HITCs) across five small island developing states (SIDS): Antigua and Barbuda, Dominica, Grenada, St. Lucia, and St. Vincent and the Grenadines (SVG). Using social security and insurance data, the model estimates coverage gains, fiscal costs, and labour market effects under varying thresholds and tax credit levels. Results show that employer mandates and HITCs can reduce coverage gaps and OOP expenditure in these countries but are highly sensitive to design characteristics. The findings offer important guidance for SIDS exploring scalable pathways towards universal health coverage through private insurance mechanisms, particularly in the absence of comprehensive public healthcare financing systems.

PMID:42473832 | DOI:10.1002/hpm.70101

Pediatr Pulmonol. 2026 Jul;61(7):e71740. doi: 10.1002/ppul.71740.

ABSTRACT

BACKGROUND: Advanced cystic fibrosis lung disease (ACFLD) remains a major cause of morbidity, particularly in individuals requiring lung transplantation. Gastrointestinal-related aspiration (GRASP), including reflux and motility disorders, may contribute to adverse respiratory outcomes, yet diagnostic and management strategies vary across specialties.

OBJECTIVE: To evaluate practice patterns in foregut testing and pharmacologic management of GRASP among pulmonologists and gastroenterologists caring for individuals with ACFLD, with and without transplantation.

METHODS: A cross-sectional survey of clinicians at cystic fibrosis centers was distributed via a national listserv. Respondents involved in ACFLD care were included. Descriptive statistics were generated, and comparisons by specialty were performed using Fisher’s exact and Mann-Whitney U tests (α = 0.05).

RESULTS: Forty-five complete responses were analyzed (82% pulmonologists, 18% gastroenterologists). Eighty percent reported access to gastrointestinal motility testing. Overall use of reflux, motility, and gastric emptying testing was similar between specialties; however, modality selection differed. Gastroenterologists favored pH multichannel intraluminal impedance (75%) and BRAVO capsule testing (25%), while pulmonologists demonstrated heterogeneous practices and frequently deferred testing (37.8%). High-resolution manometry was universally preferred by gastroenterologists but variably used by pulmonologists. Acid suppression was widely utilized, with proton pump inhibitors most common, though pulmonologists showed greater variability, particularly post-transplant.

CONCLUSIONS: Substantial variability exists in GRASP evaluation and management in ACFLD. Standardized, multidisciplinary approaches may improve diagnostic consistency and optimize outcomes, especially in the transplant population.

PMID:42473831 | DOI:10.1002/ppul.71740